PROGNYX

Home/The Watchtower/Trastuzumab deruxtecan

Drug file · From the Watchtower

Trastuzumab deruxtecan: the briefings and the record

Every Prognyx briefing on trastuzumab deruxtecan, newest first, and the dated events drawn from the sources those briefings cite. Rebuilt with each new briefing.

Also known as
T-DXd, Enhertu, DS-8201
Target, as briefed
HER2
Companies named
AstraZeneca, Daiichi Sankyo
Prognyx coverage
3 briefings, 17 June 2026 to 15 September 2026

Prognyx briefings on trastuzumab deruxtecan

  1. first-line HER2-mutant advanced non-small cell lung cancerEnhertu posts 14.3-month first-line PFS in HER2-mutant NSCLC (DESTINY-Lung04)

    AstraZeneca reports a Phase III first-line PFS win over the immunotherapy-chemo standard; the hazard ratio and overall survival are not yet disclosed.

  2. First-line HER2-positive metastatic breast cancerEnhertu plus pertuzumab wins EU first-line HER2-positive metastatic breast cancer approval

    AstraZeneca says the European approval creates the first new first-line HER2-positive metastatic breast cancer regimen in more than a decade; the supplied dossier did not include an EMA/EC label, EPAR, pivotal trial identifier, or efficacy table behind the decision.

  3. First-line HER2-positive gastric/gastroesophageal junction adenocarcinomaAstraZeneca's NCT06764875 pits a rilvegostomig–Enhertu regimen against the pembrolizumab comparator in first-line HER2+ gastric cancer

    A three-arm, 840-patient Phase 3, recruiting now, primary completion estimated April 2029, tests AstraZeneca's largely owned rilvegostomig-plus-Enhertu combination against trastuzumab + chemotherapy + pembrolizumab.

Sourced timeline

Readouts, regulatory actions, filings, trial starts and deals that the Prognyx engine extracted from the documents cited in these briefings, newest first. Each links to its source and to the briefing that cited it. Press coverage is left out, and so is any event dated on its own briefing's day: the briefing above is the record for that day. A month without a day is a date the source gave only to the month.

  1. ReadoutDESTINY-Lung04 median PFS reaches 14.3 monthsAstraZeneca newsroom · cited in Enhertu posts 14.3-month first-line PFS in HER2-mutant NSCLC (D…
  2. Regulatory actionEnhertu plus pertuzumab EU approval announcedSEC 6-K · cited in FDA grants accelerated approval to AstraZeneca's Etcamah (camiz…
  3. ReadoutDESTINY-Lung04 demonstrates significant first-line PFS benefitSEC 6-K · cited in Enhertu posts 14.3-month first-line PFS in HER2-mutant NSCLC (D…

Registered trials on file

ClinicalTrials.gov records that the cited sources tie to trastuzumab deruxtecan, each opening on the registry.

Want this on your pipeline?
Get a free sample competitive brief on one of your assets, sourced, sharp, no strings.
Request a sample brief → Or read how Prognyx runs continuous oncology competitive intelligence.

Prognyx briefings are built from public information and reflect Prognyx's analysis. They are not investment advice and do not promote any product or off-label use. Event titles are written by the Prognyx engine from the linked source; the source is the record.